Mutational and Functional Analysis Reveals ADAMTS18 Metalloproteinase as a Novel Oncogene in Melanoma

Xiaomu Wei¹, Todd D. Prickett¹, Cristina G. Viloria², Alfredo Molinolo³, Jimmy C. Lin⁴, Isabel Cardenas-Navia¹, Pedro Cruz¹, NISC Comparative Sequencing Program¹, Steven A. Rosenberg⁵, Michael A. Davies⁶, Jeffrey E. Gershenwald⁷,⁹, Carlos López-Otin², and Yardena Samuels¹,*

¹National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA
²Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006-Oviedo, Spain
³Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA
⁴Ludwig Center for Cancer Genetics and Therapeutics, and Howard Hughes Medical Institute at the Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231
⁵National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
⁶Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030
⁷Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030
⁸Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030
⁹Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, 77030

Abstract

The disintegrin-metalloproteinasises with thrombospondin domains (ADAMTS) genes have been suggested to function as tumor suppressors as several have been found to be epigenetically silenced in various cancers. We performed a mutational analysis of the ADAMTS gene family in human melanoma and identified a large fraction of melanomas to harbor somatic mutations. To evaluate the functional consequences of the most commonly mutated gene, ADAMTS18, six of its mutations were biologically examined. ADAMTS18 mutations had little effect on melanoma cell growth under standard conditions, but reduced cell dependence on growth factors. ADAMTS18 mutations also reduced adhesion to laminin and increased migration in vitro and metastasis in vivo. Melanoma cells expressing mutant ADAMTS18 had reduced cell migration after shRNA-mediated knockdown of ADAMTS18, suggesting that ADAMTS18 mutations are growth-, migration- and metastasis-promoting in melanoma.

*To whom correspondence should be addressed: National Human Genome Research Institute, 50 South Drive, MSC 8000, Building 50, Room 5140, Bethesda MD 20892-8000, Phone: 301-451-2628, Fax: 301-480-9864, samuelsy@mail.nih.gov.
#These authors contributed equally to this work.
Introduction

It is widely accepted that genetics plays a major role in cancer development (1). The progression of melanoma, which is one of the most aggressive forms of skin cancer (2) is known to be accompanied by a series of genetic changes that affect at least several oncogenes and tumor suppressor genes (3). Further identification of such genes in melanoma is crucial to promote our understanding of the disease and to develop successful molecular targeted therapies. In this study, we systematically evaluated the disintegrin-metalloproteinases with thrombospondin domains (ADAMTS) genes through their comprehensive mutational analysis in melanoma.

The ADAMTS gene family is part of a superfamily of zinc-based proteinases, the metzincins (4). The matrix metalloproteinase (MMP) enzymes which also belong to the metzincins superfamily have recently been shown to be highly mutated in melanoma (5). All the ADAMTS proteins have proteolytic potential, but have not yet been studied in great detail in cancer (6). There is, however, an emerging concept that a number of ADAMTSs may have tumor suppressor activities (6–8). In particular, Viloria et al have recently shown that ADAMTS15 is somatically mutated in colorectal cancer and functional evaluation of its mutations revealed it to be a tumor suppressor gene (7). As ADAMTS genes encode extracellular proteins, their accessibility to systematically delivered drugs makes them excellent therapeutic targets.

In the current study, we examined melanoma samples for somatic mutations in 19 human genes that encode ADAMTS proteins. Remarkably, we found that one ADAMTS gene, ADAMTS18, which was highly mutated in melanoma was previously found to be a candidate cancer gene (CAN gene) in large scale whole exome sequencing of colorectal cancer (9,10). In addition to the ability of the mutated versions of this gene to cause increased proliferation of melanoma cells, we found that they increased cell migration and metastasis. These results suggest that genetic alteration of ADAMTS18 plays a major role in melanoma tumorigenesis.

Results and Discussion

Comprehensive mutational analysis of the ADAMTS gene family in human melanoma

The human ADAMTS family consists of 19 genes (Supplementary Table 1). To evaluate whether these are genetically altered in melanoma, we analyzed the coding exons of this gene superfamily in 31 melanoma patients. A total of 408 exons from the ADAMTSs were extracted from genomic databases. These exons were amplified by using polymerase chain reaction (PCR) from tumor genomic DNA samples using the primers listed in Supplementary Table 2 and directly sequenced with dye terminator chemistry. We then determined whether a mutation was somatic (i.e., tumor-specific) by examining the sequence of the gene in genomic DNA from normal tissue of the relevant patient. From the ~8 Mb of sequence information obtained, we identified eleven genes containing somatic mutations (Table 1). Genes found to have one non-synonymous mutation or more were then further analyzed for mutations in an additional 48 melanomas. Through this approach, we identified 54 mutations in 11 genes, thus affecting 37% of the melanoma tumors analyzed (Table 1 and examples in Figure 1A). The number of C>T mutations in the melanoma tumors was significantly greater than other nucleotide substitutions resulting in a high prevalence of C:G>T:A transitions (p<0.0001) (Supplementary Figure 1), confirming previously reported melanoma signatures (11).

ADAMTS18 is highly mutated in melanoma

In order to evaluate the most highly mutated gene, ADAMTS18 (affecting ~18% of cases analyzed), we further extended our sequencing analysis to an additional human melanoma
tumor panel consisting of 65 melanoma specimens (12). In this screen we detected 10 nonsilent somatic mutations and one silent somatic mutation, affecting approximately 14% of the cases analyzed (Supplementary Table 3 and examples in Supplementary Figure 2A), thus reaching a similar frequency of mutations observed in the first melanoma set. The mutations that arise during tumorigenesis may give a selective advantage to the tumor cell (driver mutations) or have no functional effect on tumor growth (passenger mutations). The combined genetic analysis of ADAMTS18 in both melanoma panels identified 24 nonsynonymous and 4 synonymous mutations, yielding a ratio of nonsynonymous to synonymous changes (N/S ratio) of 6:1; this is significantly higher than the N/S ratio of 2:1 predicted for nonselected passenger mutations \( (P < 0.004) \) (9). These data are consistent with the hypothesis that mutations in ADAMTS18 are positively selected for during tumorigenesis.

ADAMTS18 has been previously reported to be mutated in kidney and colorectal cancer (9,10) and (http://www.sanger.ac.uk/genetics/CGP/Census/). Importantly, two of the previous mutations reported in colorectal cancer lie near our reported mutations (K455T and 2085_2086insT). We therefore expanded our study to encompass 50 colorectal cancer samples. These studies revealed mutations in ADAMTS18 in 4 of 50 colorectal cancer samples all of which were somatic (Supplementary Figure 2B). Interestingly, two of these mutations occurred exactly at the same location and cause the deletion of the same region as did the mutations in melanoma samples 98T and 85T (Table 1). A schematic representation of ADAMTS18 protein and the location of all the mutations identified is presented in Figure 1B. The clinical information associated with the melanoma and colorectal tumors containing somatic ADAMTS mutations is provided in Supplementary Table 4.

**ADAMTS18 mutations promote growth factor-independent cell proliferation**

To evaluate the effect of some of these mutations on ADAMTS function, we decided to focus on ADAMTS18, which was the most highly mutated gene, harboring 14 somatic mutations in our initial screen (Table 1). The large number of mutations identified in ADAMTS18 as well as the fact that the affected residues in ADAMTS18 are highly conserved evolutionarily, retaining identity in rat and mouse, suggests that these mutations may be functionally important in melanoma.

To assess the effects of ADAMTS18 mutations on tumorigenic phenotypes, we created stable clones expressing wild-type or six tumor-derived ADAMTS18 mutants (G312E, P452S, C638S, Q904X, Q1002X, P1035S) in two different human melanoma cell lines (A375 and Mel-STR (13)), both of which were confirmed to harbor wild-type ADAMTS18. We chose to focus on these six particular mutations as these were found in important functional domains and showed high species conservation. Western blot analysis showed a similar expression level of ADAMT18 in A375 cells in all clones except mutations Q904X and P1035S, which had lower expression levels (Supplementary Figure 3). These clones were used for succeeding studies.

We first assessed the transformation abilities of the ADAMTS18 mutants. As seen in Figures 2Ai–ii, expression of all the ADAMTS18 mutants in either A375 or Mel-STR cells (except mutant Q1002X in Mel-STR cells) elicited a significantly higher cell transformation ability compared to clones expressing vector or wild-type ADAMTS18 \( (P < 0.05, \text{ t test}) \). When the same set of clones was evaluated for growth it was apparent that expression of wild-type or mutant ADAMTS18 genes did not affect the growth rate of A375 and Mel-STR cells in tissue culture in the presence of media with 10% serum (Figure 2Bi–ii). However, if the serum concentration was reduced to 2.5% (for A375 cells) or 1% (for Mel-STR cells), wild-type clones grew at a slower rate than mutant clones on plastic (Fig. 2Bi–iv).
Mutant ADAMTS18 increases cell migration through modulation of cell adhesion

ADAMTS18 is a secretory protein and similarly to virtually all ADAMTS family members it is strongly associated with the extracellular matrix at the pericellular space. This location likely facilitates the interaction of ADAMTS18 with integrins and other extracellular matrix components as well as with growth factors such as VEGF and HGF (14). To test whether mutant forms of ADAMTS18 have alterations in these interactions, we performed an adhesion assay using either fibronectin or laminin type-1 as substrates. Analysis of cell adhesion to these extracellular matrix components revealed that wild-type ADAMTS18 expressing cells had an increased adhesion to laminin-I when compared with cells expressing the ADAMTS18 mutations (Fig. 3Ai). In contrast, adhesion to fibronectin was similar between wild-type and mutant ADAMTS18 expressing cells (Fig. 3Aii).

Alterations in adhesion have previously been shown to lead to changes in signaling properties. Based on the above results mutant forms of ADAMTS18 will likely have profound effects on signaling proteins that have the ability to induce changes in gene expression programs. These effects on gene expression will ultimately result in further differences in cell adhesion and migration between ADAMTS18-mutant cells and wild-type cells. This situation is not unprecedented and it has been previously described in detail for other extracellular metalloproteinases including members of the ADAMTS family such as ADAMTS12 (15–17).

It has previously been shown that mutations in ADAMTS genes can affect their cell localization (7). To test whether the identified mutations affect their localization, we immunoprecipitated concentrated conditioned media or cell lysates derived from the A375 pooled clones using FLAG-M2 beads followed by western blot analysis. Equal levels of FLAG tagged ADAMTS18 bands were seen in immunoprecipitated cell lysates expressing WT and mutant ADAMTS18 immunoblotted for FLAG (Figure 3Bi). However, only WT ADAMTS18 was observed in immunoprecipitates from conditioned medium using the same clones (Figure 3Bi). Similar results were observed when the same clones were analyzed by immunofluorescent staining. As seen in Figure 3Bii, more total protein is retained and attached to the cell surface for mutant ADAMTS18 expressing cells, explaining its absence in the conditioned medium. In contrast, immunostaining of WT ADAMTS18 expressing cells revealed diminished cell surface localization of FLAG tagged WT protein (Figure 3Bii). The effect of ADAMTS18 mutations on its localization could be the underlying mechanism for the differential adhesion described above.

As previous studies reported that reduced adhesion facilitates cell migration (18,19), our finding that cells expressing mutant ADAMTS18 have reduced laminin-1 adhesion prompted us to investigate whether these cells also have increased migration ability. Boyden chamber assays showed that A375 mutant ADAMTS18 expressing clones had an increased ability to migrate through porous membrane (Fig. 3Ci–ii) (P < 0.05, t test). On the basis of these results, we can postulate that ADAMTS18 modulates cell adhesion, and this might be a candidate mechanism to explain how mutated forms of this protease stimulate cell migration.

Mutant ADAMTS18 is required for migration in melanoma cells

To assess whether melanoma cells harboring endogenous ADAMTS18 mutations are dependent on ADAMTS18 for migration, we used short hairpin RNA (shRNA) to stably knock down ADAMTS18 in melanoma lines harboring either wild-type (5T, A375) or mutant ADAMTS18 (85T, Q1002X; 12T, P452S). We confirmed specific targeting of ADAMTS18 by shRNAs in transfected HEK 293T cells as well as in one of the melanoma cell lines by RT-PCR (Supplementary Figures 4A and 4B). Two unique shRNA constructs...
targeting ADAMTS18 had minimal effect on the migration of cells expressing wild-type protease but substantially reduced the migration of melanoma lines carrying mutant ADAMTS18 (Fig. 3Di–vi). Thus, mutant ADAMTS18 is essential for the migration of melanoma cells harboring these mutations.

**Mutant ADAMTS18 causes increased metastases in vivo**

To determine whether the ADAMTS18 mutations affect growth in vivo, Mel-STR clones expressing empty vector, wild-type or mutant ADAMTS18 were subcutaneously injected into NOD/SCID mice. Twenty two days after injection, the mice were evaluated for skin ulceration as well as metastasis formation by examining hematoxylin/eosin (H&E) stained sections of paraffin embedded lungs. As seen in Figure 4A, most of the tumors expressing mutant ADAMTS18 presented with ulcerations whereas few of the mice with cells expressing wild-type ADAMTS18 had ulcerating lesions. In addition, most mice injected with mutant ADAMTS18 expressing cells had micrometastases. In contrast, no lung metastases were found in the mice injected with wild-type clones (Figures 4B and 4C). This suggests that, in some cases, ADAMTS18 may have an assay-specific suppressive effect. This scenario has precedent and has been described for Mdm2 (20). Although the underlying mechanism for the lack of a metastatic phenotype seen in the wild-type cells is unclear, it is consistent with ADAMTS proteins being inhibited by proteins such as TIMPs (Tissue Inhibitor of Metalloproteinases) in vivo (21). It must be noted, though, that the number of identified endogenous protease inhibitors is significantly lower than that of proteases (22). It is therefore conceivable that another, as yet unknown, ADAMTS18 inhibitor is being expressed in vivo, specifically inhibiting the metastasis of cells expressing wild-type ADAMTS18.

Clearly, ADAMTS18 mutations are dispersed throughout its domains. This is reminiscent to the driver mutations reported in ERBB4 (23), CARD11 (24) and FLT3 (25). In addition to the catalytic domain, ADAMTS proteins have non-catalytic ancillary domains that regulate interaction of the protein with substrates or inhibitors such as the TIMPs, and these domains have been shown to mediate recognition and cleavage of numerous substrates (26–28). Furthermore, the ancillary domain of several ADAMTS proteins is modified by C-terminal proteolysis (29–31), which might alter substrate recognition and enzyme localization. As several of the mutations identified in ADAMTS18 lie within the C-terminus and some cause its truncation, they might affect this recognition. Thus elucidation of the specific interactions of ADAMTS18 with particular substrate(s) will provide an important understanding of the biochemical effects of the discovered mutations. Recently, a novel method of detecting protease substrates has been developed by Kleifeld et al (32). Upon radioisotopic labeling of the N-termini amine groups of cellular proteins and enzymatic reaction with known proteases, fragmented peptides are purified and run on a MS/MS thus identifying new cleavage sites. Utilization of such a detection method in determining the physiological substrates for ADAMTS18 will prove beneficial.

As mentioned above, several ADAMTSs have been suggested to harbor antitumorigenic properties (33,34). These reports focused on the anti-angiogenic effects of ADAMTS1 and ADAMTS8 (35,36) as well as the modulation of the extracellular signal-regulated kinase (ERK) pathway by ADAMTS12 through extracellular matrix (ECM) interactions (15). El Hour et al demonstrated that lack of ADAMTS12 in mice resulted in increased angiogenesis and tumor progression (37). In addition, ADAMTS15 was shown to have a protective role in breast cancer as increased expression along with decreased expression of ADAMTS8 resulted in prolonged relapse-free progression in these patients (38). Genetic inactivation of ADAMTS15 via somatic mutation lead to decreased ability to suppress colony-formation or invasion of colorectal cancer cells compared with expression of the wild-type gene (7). Furthermore, epigenetic silencing of ADAMTS genes such as ADAMTS9 or ADAMTS18

*Mol Cancer Res.* Author manuscript; available in PMC 2011 November 1.
has been observed in different types of carcinomas implying them to be tumor suppressors (39,40)

Conversely, genetic silencing of ADAMTS20 in mice resulted in increased melanoblast apoptosis, decreased soluble Kit ligand (sKitl) stimulation of the pro-survival pathway, and decreased processing of the ECM protein versican (41). These results suggest that ADAMTS20 is a pro-survival molecule that might act as an oncogene in melanoma. This is supported by the observation that ADAMTS20 is overexpressed in brain, colon and breast cancers (42). Importantly, ADAMTS20 was the second most highly mutated gene in our study harboring 12 somatic mutations (11.4%). Future functional evaluation of the identified mutations in ADAMTS20 will further verify whether ADAMTS20 participates in melanoma progression.

Taken together, our results provide genetic, cellular and in vivo evidence that ADAMTS18 has a role in promoting melanoma tumorigenesis. We postulate that the genetic alteration of ADAMTS18 contributes to the aggressive biological behavior of melanoma through modulation of proliferative, migratory and metastatic mechanisms. Importantly, this is the first genetic identification of an ADAMTS gene that is functionally proven to have an oncogenic role in human disease.

Materials and Methods

Tumor Tissues

Tissue and melanoma cell lines used for the discovery and first validation in this study were described previously (5).

For the melanoma second validation set, Optimum cutting temperature (OCT)–embedded frozen clinical specimens were obtained from the Melanoma Informatics, Tissue Resource, and Pathology Core, and the Central Nervous System Tissue Bank at The University of Texas M. D. Anderson Cancer Center under Institutional Review Board-approved protocols. H&E-guided dissection and isolation of DNA from the tumor-enriched isolates has been described previously (12).

PCR, sequencing and mutational analysis of melanoma samples

PCR and sequencing was done as previously described (5,7,23). The primary phase mutation screen was analyzed using Consed (43). Variants were called using Polyphred 6.11 (44) and DIPDetector, an indel detector for improved sensitivity in finding insertions and deletions. Sequence traces of the secondary screen were analyzed using the Mutation Surveyor software package (SoftGenetics, State College, PA).

To increase our confidence that the mutations in the M. D. Anderson set, for which no matched normal DNA sample was available, did not represent germline polymorphisms, we searched the corresponding exons of ADAMTS18 in a total of 145 DNA samples and detected no abnormalities.

Construction of wild-type and mutant ADAMTS18 expression vector

Human ADAMTS18 (NM _199355.2) was cloned by PCR as previously described (5) using a clone (#30343625) purchased from Open Biosystems with primers in Supplementary Table S5. The PCR product was cloned into the mammalian expression vector pCDF-MCS2-EF1-Puro™ (Systems Biosciences, Inc., Mountain View, CA) or pCDNA3.1 (−) (Invitrogen) via the XbaI and NotI restriction sites. The G312E, P452S, C638S, Q904X, Q1002X, and
P1035S point mutants were made using Phusion PCR for site-directed mutagenesis using the primers listed in Supplementary Table S5.

**Cell culture and transient expression**

Metastatic melanoma tumor lines were maintained as previously described (45). HEK 293T cells were purchased from ATCC (Manassas, VA) and maintained in complete Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS), 1× non-essential amino acids, 2 mM L-glutamine, and 0.75% sodium bicarbonate. A375 cells were purchased from National Cancer Institute, Division of Cancer Treatment, Developmental Therapeutics Program, Frederick, MD and maintained in RPMI-1640 and supplemented with 10% FBS. Mel-STR cells were described previously(5). HEK 293T cells were transfected with Lipofectamine2000 reagent (Invitrogen, Carlsbad, CA) at a 6:1 ratio with DNA (µl:µg) using 3–5 µg of plasmid DNA per T75 flask.

**Immunoprecipitation and western blotting**

Transfected cells were gently washed 3× in PBS and then lysed using 0.5–1.0 mL 1% NP-40 lysis buffer (1% NP-40, 50mM Tris-HCl pH 7.5, 150mM NaCl, Complete Protease Inhibitor tablet, EDTA-free (Roche, Indianapolis, IN), 1µM sodium orthovanadate, 1 mM sodium fluoride, and 0.1% β-mercaptoethanol) per T-75 flask, for 20 min on ice. Lysed cells were scraped and transferred into a 1.5 mL microcentrifuge tube. Extracts were centrifuged for 10 min at 14,000 rpm at 4°C. 500 µl of supernatant was immunoprecipitated overnight using 20 µL of anti-FLAG (M2) beads (Sigma-Aldrich A2220). Immunoprecipitation of conditioned medium was done as previously described (5). The immunoprecipitates were washed and subjected to SDS-PAGE and western blotting as previously described (46). Primary antibodies used in our analysis were anti-FLAG horseradish peroxidase conjugated (Sigma-Aldrich A8592) and anti-alpha-tubulin (Calbiochem-EMD Biosciences, Gibbstown, NJ CP06).

**Pooled stable expression**

To make lentivirus, pCDF-MCS2-EF1-Puro \textit{ADAMTS18} constructs were co-transfected into HEK 293T cells seeded at 1.5×10^6 per T75 flask with pVSV-G and pFIV-34N (kind gifts from Todd Waldman, Georgetown University) helper plasmids using Lipofectamine 2000 as described by the manufacturer. Virus-containing media was harvested 48–60hr after transfection, filtered, aliquoted and stored at −80°C.

A375 cells were seeded at 1.5 × 10^6 cells per T75 flask 24 hr prior to infection. Lentivirus for \textit{ADAMTS18} (WT, G312E, P452S, C638S, Q904X, Q1002X, and P1035S) or empty vector control were used to infect A375 cells as previously described(47). Stable expression of \textit{ADAMTS18} proteins (WT and mutants) was determined by SDS-PAGE analysis followed by immunoprecipitation and immunoblotting with anti-FLAG and anti-alpha-tubulin to show equivalent expression among pooled clones.

Mel-STR cells were seeded at 1.5×10^6 per T75 flask 24 hr prior to transfection with \textit{ADAMTS18} (WT, G312E, P452S, C638S, Q904X, Q1002X, and P1035S) or empty vector control in pcDNA3.1(−) using Fugene6 (Roche 11814443001) as per manufacturers protocol. Transfected cells were selected using normal complete growth medium supplemented with 300µg/ml G418 and pooled for future experiments. Stable expression of \textit{ADAMTS18} proteins (WT and mutants) was determined by SDS-PAGE analysis followed by immunoprecipitation and immunoblotting with anti-FLAG and anti-alpha-tubulin to show equivalent expression among pools.
Lentiviral shRNA

Constructs for stable depletion of ADAMTS18 were obtained from Open Biosystems (Huntsville, AL) and two were confirmed to efficiently knockdown ADAMTS18 at the message and protein level. Lentiviral stocks were prepared as previously described (5). Melanoma cell lines (5T, 12T, 85T and A375) were infected with shRNA lentiviruses for each condition (vector and scrambled controls and three independent ADAMTS18-specific shRNAs whose sequences are presented in Supplementary table S6). Selection and growth were done as described above. Stably infected pooled clones were tested in functional assays.

Reverse Transcription PCR

Total RNA was extracted from pooled clones of melanoma cells A375 stably knocked-down for endogenous ADAMTS18 following the manufacturer’s protocol for RNeasy Mini Kit (Qiagen #74101). Total RNA was eluted in 30 µl DEPC-treated dH2O. A total of 1µg of total RNA was used for single strand cDNA synthesis using a SuperScript III First Strand kit (Invitrogen #18080-051). cDNA was amplified using the oligo dT20 primer supplied in the kit. To test for loss of ADAMTS18 message we used 1 µl of cDNA in the PCR with either ADAMTS18 primers (forward primer: 5´-accctggtctcagtgttcca-3´ and reverse primer: 5´-tgcaaggtctcttccaagtcc-3´), (forward primer: 5´-cggctagaacctggacagaa-3´ and reverse primer: 5´-eggctgaaacgggacagaa-3´) or GAPDH primers (forward primer: 5´-tggaaggactcatgaccaca-3´ and reverse primer: 5´-tgctgtagccaaattcgttg-3´). The product was then analyzed on a 1% agarose gel.

Proliferation assays

To examine growth potential, pooled A375 and Mel-STR ADAMTS18 clones were seeded into 96 well plates at 250 cells per well in either 1%, 2.5% or 10% serum-containing medium and incubated for 13–17 days. Cell numbers were counted every 48 hr by lysing cells in 50 µl 0.2% SDS/well and incubating for 2 hours at 37°C prior to addition of 150 µl/well of SYBR Green I solution (1:750 SYBR Green I (Invitrogen-Molecular Probes) diluted in dH2O). Plates were analyzed using a BMG Labtech FLOUstar Optima.

Foci formation assays

A375 and Mel-STR pooled clones were seeded at 500 cells per T25 flask in normal complete serum containing medium and incubated for 8–10 days prior to staining with Hema 3 Stat Pack (Protocol) to visualize foci for counting.

Migration assays

A375 or melanoma cells with stable knock-down of ADAMTS18 were seeded into pre-conditioned migration wells (8.0 µm – BD Biocoat, BD Biosciences) at 10,000 to 30,000 cells per well in serum-free medium in the top chamber and incubated for 16–18 hr with complete serum containing medium in the bottom chamber prior to harvesting. Inserts were fixed and stained using Hema 3 Stat Pack (Protocol). Inserts were analyzed and counted for cells migrated per field view and quantitated using ImageJ (NIH software).

Adhesion assay

96-well plates were coated with 5 µg/ml laminin-I or 5 µg/ml fibronectin in 200ul 1×PBS and incubated overnight at 4°C. Prior to plating cells the coated wells were washed once in PBS and then blocked with 0.1mg/ml heat-inactivated BSA (dissolved in PBS) for 1 hr at room temperature. Cells were seeded into the plates at 30,000 cells per well and incubated at 37°C for 2 hr with the lid off. Cells were shaken off plate vigorously then washed three times with PBS. Remaining cells were fixed using 4% paraformaldehyde in PBS overnight.
at 4°C. Plates were then washed three times using ddH2O. Attached cells were stained with 0.1% crystal violet (w/v – 20% methanol in PBS) for 30 min at room temperature followed by three washes with dd H2O. Dye was solubilized with 0.1N HCl for 10 min at room temperature. Absorbance was measured at 610nm on Molecular Devices SpectraMax and quantitated using Microsoft Excel.

**Immunoflourescent analysis of pooled clones**

A375 pooled ADAMTS18 clones expressing either (WT, G312E, C638S and P1035S) or empty vector were seeded on 8-well chamber slides at a cell density of 50,000 cells per well. Cells were grown for 24 hr prior to fixing and staining. Chamber slides were wased once with 1× PBS followed by fixation with 4% paraformaldehyde (PBS) for 15 min at room temperature. Cells were subsequently washed three times with ice-cold 1× PBS for 5 min per wash. Slides were blocked with 1% BSA (PBS-T) for 30–60 min at room temperature followed by washing with 1× PBS twice. Chamber slides were immunostained with anti-FLAG (rabbit) (Sigma-cat# F7425) in 1% BSA (PBS-T) at a dilution of 1:50 for 18 hr at 4°C. Chamber slides were washed three times with PBS at 5 min per wash followed by incubation with anti-rabbit (Alexa fluor 568-cat# A11036) (Invitrogen, Carlsbad, CA) diluted at 1:200 in 1% BSA (PBS-T) for 2 hr at room temperature. Slides were washed three times in PBS followed by fixation/mounting with DAPI and analyzed on a Zeiss A×10 (Scope.A1) at 40× using SPOT imaging software for image acquisition. Further analysis was done using Adobe Photoshop and ImageJ/NIH software.

**Xenograft Studies in Mice**

NOD/SCID mice were purchased from Jackson Laboratories. All mice were housed in a pathogen-free facility and were given autoclaved food and water. Mel-STR pooled clones expressing empty vector or with wild-type ADAMTS18 or mutant ADAMTS18 were grown up in T-75 flasks to 70–80% confluency. 1×10^6 cells were resuspended in 100 µL of sterile 1×PBS and injected subcutaneously into 11 week old male NOD/SCID mice. Mice were monitored bi-weekly and final tumor weights were measured after tumor was excised from euthanized mice at day 22 post-injection. Lungs from each mouse were harvested in 4% paraformaldehyde and embedded in paraffin for H&E staining followed by histological evaluation.

**Statistical analysis**

Statistical analyses were performed using the R statistical environment and Microsoft Excel (two-tailed t-test, binomial test).

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

We thank for technical assistance Allison Burrell, Catherine Y. Cheng and Dr. Kristin E. Yates. We thank Dr. Robert Weinberg for the Mel-STR cell line and Dr. Gabriel Capellá for colorectal cancer samples. We also thank Drs Lynn Matrisian, Sunee Apte, Daniel McCulloch and Paul Meltzer, for their helpful comments. We also thank members of the NISC Comparative Sequencing Program for providing leadership in the generation of the sequence data analyzed here. Funded by the National Human Genome Research Institute, National Institutes of Health to Y.S. and Ministerio de Ciencia e Innovación-Spain, Fundación “M. Botín”, and European Union (FP7 MicroEnviMet) to C.L-O. Supported in part by the University of Texas M. D. Anderson Cancer Center Melanoma Specialized Programs of Research Excellence (SPORE) and the Melanoma Informatics, Tissue Resource, and Pathology Core (grant P50 CA93459).
References


Figure 1. Somatic mutations identified in ADAMTS18 in different cancer types

(A) Representative sequence chromatograms of mutations identified in ADAMTS18. In each case, the lower sequence chromatogram was from melanoma tumor. The top sequence chromatograms were from normal tissue of the relevant patient. Arrows indicate the location of missense mutations. The nucleotide and amino acid alterations are shown at the bottom of each chromatogram. (B) Protein schematic of ADAMTS18 is presented with conserved functional domains indicated as colored blocks. Black arrow heads indicate positions of nonsynonymous somatic mutations identified in 79 melanoma specimens. Mutations found in the validation melanoma or colorectal specimens are labeled as red or blue arrows, respectively. The mutations analyzed in this study are indicated with an asterisk. Propep
Reprolysin family propeptide domain; Repro: Reprolysin family zinc metalloprotease domain; ACR: ADAM cysteine-rich domain; TS: Thrombospondin type 1 domain; Spacer: ADAMTS Spacer 1 domain; PLAC: Protease and lacunin domain.
Figure 2. Mutant ADAMTS18 causes reduced cell dependence on growth factors
(A) Focus formation assay of A375 (i) or Mel-STR (ii) pooled clones expressing the indicated constructs was performed. Graph indicates number of colonies observed after two weeks of growth. (B) Cellular proliferation of A375 (i and iii) or Mel-STR (ii and iv) pooled clones transduced with an empty vector, wild-type ADAMTS18 or the indicated ADAMTS18 mutants was assessed in plastic culture plates in the presence of 10% serum (i and ii), or reduced serum (iii and iv) for 12 days. Average cell number at each time point was measured by determining DNA content in eight replicate wells using SYBR Green I.
Figure 3. Mutant ADAMTS18 is essential for melanoma cell migration possibly through modulating cell adhesion

(A) Adhesion assay of A375 clones expressing the indicated constructs was performed. Laminin-I (i) or fibronectin (ii) coated plates were assessed for adhesion after 1hr incubation by crystal violet staining. Plates were analyzed by reading the absorbance at 610nm. (B) Localization of ADAMTS18 proteins were assessed using immunoprecipitation and immunofluorescent staining. (i) Cellular condition media and lysates were immunoprecipitated using anti-FLAG (M2) beads and analyzed by western blot analysis. Cell lysates were blotted with anti-alpha-tubulin as a loading control. (ii) A375 pooled ADAMTS-18 clones (WT, G312E, C638S, P1035S or empty vector) were plated and fixed

Mol Cancer Res. Author manuscript; available in PMC 2011 November 1.
on slides for immunofluorescent staining with anti-FLAG and DAPI for nuclear localization. (C) A375 clones expressing the indicated constructs were grown in Boyden chambers and assessed for their ability to migrate. (i) Graph indicates the number of cells that migrated 18 hr after seeding (ii) Representative pictures of migrated cells. (D) Melanoma cell lines expressing wild-type ADAMTS18 (i and ii) or mutant ADAMTS18 (iii and iv) were infected with either control shRNAs or two different shRNA constructs targeted against ADAMTS18 (#4 and #5). Migration ability of the cells was assessed and plotted. Representative images of migrated cells are shown in v and vi.
Figure 4. Mutant ADAMTS18 cause increased lung metastasis in vivo
Mel-STR clones expressing empty vector, wild-type or mutant ADAMTS18 (G312E, C638S, Q904X, P1035S) were subcutaneously injected into NOD/SCID mice. 22 days after injection, the mice were evaluated for lung metastasis formation by examining hematoxylin/eosin (H&E) stained sections of paraffin embedded lungs. (A) Graph shows the number of mice with ulcerations where 0.5 was used to score minor tumor ulcerations (< 2mm) and 1 was used to score major ulcerative tumors (~5–30mm). (B) Graph indicates the number of mice that had lung metastases. (C) Representative images of lung sections showing patterns of metastatic spread of the different mutants and the vector control are presented. (i) Mutant G312E mice, a group of neoplastic cells have impacted into a blood vessel. The malignant
cells are beginning to grow into the lung parenchyma (arrow). The inset at higher magnification shows the characteristic atypia and an apoptotic cell (arrow). (ii) Mutant C638S mice, the metastatic tumor is actively growing and has invaded the surrounding lung tissues. Two bronchi are trapped within the tumor (arrows). Several mitoses are shown in the inset. (iii) Mutant C638S mice, the invading neoplastic tissue grows surrounding a bronchial structure (arrow). The atypia of the malignant cells is evident in the inset. (iv) Mutant Q904X mice, a web-like network of malignant cell is expanding into the lung parenchyma, spilling into alveolar spaces (black arrow). Disruption of the alveolar walls due to altered mechanical properties of the lung tissue is evident in the area surrounding the metastasis (white arrow). (v) Mutant P1035S mice, a group of neoplastic cells have impacted into a blood vessel, and tumor expansions are already growing into the lung (arrow). The cancer cells are shown at a higher magnification in the inset. (vi) Vector mice, a subpleural (black arrow, pleura) metastatic growth (white arrow) is growing into the lung parenchyma. The atypia of the neoplastic cells is shown in the inset.
Table 1

Mutations Identified in ADAMTSs

<table>
<thead>
<tr>
<th>Gene</th>
<th>Ref Seq accession*</th>
<th>CCDS accession*</th>
<th>No. of mutations (% tumors affected)</th>
<th>Tumor</th>
<th>Exon</th>
<th>Nucleotide‡</th>
<th>Amino Acid‡</th>
<th>Functional domain</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADAMTS2</td>
<td>NM_014244.1</td>
<td>CCDS4444.1</td>
<td>5 (5.1%)</td>
<td>71T</td>
<td>3</td>
<td>C655T</td>
<td>P219S</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>104T</td>
<td>12</td>
<td>G1891A</td>
<td>D631N</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>104T</td>
<td>18</td>
<td>C2713T</td>
<td>R905C</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>85T</td>
<td>19</td>
<td>C2858T</td>
<td>S953F</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>55T</td>
<td>22</td>
<td>C3430T</td>
<td>L1444F</td>
<td>None</td>
</tr>
<tr>
<td>ADAMTS3</td>
<td>NM_014243</td>
<td>CCDS3553.1</td>
<td>1 (1.3%)</td>
<td>32T</td>
<td>22</td>
<td>C3277T</td>
<td>H1093Y</td>
<td>None</td>
</tr>
<tr>
<td>ADAMTS6</td>
<td>NM_197941</td>
<td>CCDS3983.2</td>
<td>3 (2.5%)</td>
<td>85T</td>
<td>3</td>
<td>C629T</td>
<td>S210L</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21T</td>
<td>10</td>
<td>G1511A</td>
<td>G504E</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21T</td>
<td>11</td>
<td>G1513A</td>
<td>E505K</td>
<td>None</td>
</tr>
<tr>
<td>ADAMTS7</td>
<td>NM_014272</td>
<td>CCDS32303.1</td>
<td>4 (5.1%)</td>
<td>83T</td>
<td>2</td>
<td>C148T</td>
<td>R50X</td>
<td>Propeptide</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>63T</td>
<td>2</td>
<td>C377T</td>
<td>P126L</td>
<td>Propeptide</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>59T</td>
<td>7</td>
<td>G1090A</td>
<td>G364S/LOH</td>
<td>Reprolysin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4T</td>
<td>16</td>
<td>G2197T</td>
<td>A733S</td>
<td>ADAM-TS Spacer 1</td>
</tr>
<tr>
<td>ADAMTS8</td>
<td>NM_007037</td>
<td>CCDS41732.1</td>
<td>3 (3.8%)</td>
<td>7T</td>
<td>5</td>
<td>C1289A</td>
<td>A430D</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16T</td>
<td>6</td>
<td>G1580A</td>
<td>G527E/LOH</td>
<td>ADAM cysteine-rich domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48T</td>
<td>7</td>
<td>G1814A</td>
<td>G605E</td>
<td>None</td>
</tr>
<tr>
<td>ADAMTS10</td>
<td>NM_030957</td>
<td>CCDS12206.1</td>
<td>4 (3.8%)</td>
<td>43T</td>
<td>15</td>
<td>G1936A</td>
<td>E646K</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>55T</td>
<td>21</td>
<td>C2750T</td>
<td>A917V</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7T</td>
<td>22</td>
<td>C2791T</td>
<td>P913S/LOH</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7T</td>
<td>23</td>
<td>G3193A</td>
<td>G1065S/LOH</td>
<td>None</td>
</tr>
<tr>
<td>ADAMTS13</td>
<td>NM_139027</td>
<td>CCDS6972.1</td>
<td>2 (2.5%)</td>
<td>33T</td>
<td>14</td>
<td>A1652G</td>
<td>D551G</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4T</td>
<td>20</td>
<td>C2495T</td>
<td>S852L</td>
<td>None</td>
</tr>
<tr>
<td>ADAMTS15</td>
<td>NM_139055</td>
<td>CCDS8488.1</td>
<td>3 (3.8%)</td>
<td>24T</td>
<td>3</td>
<td>G1237A</td>
<td>D413N</td>
<td>Reprolysin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32T</td>
<td>8</td>
<td>C2548T</td>
<td>P850S</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48T</td>
<td>8</td>
<td>C2642T</td>
<td>A881V</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td>ADAMTS18</td>
<td>NM_199355</td>
<td>CCDS10926.1</td>
<td>14 (17.7%)</td>
<td>13T</td>
<td>3</td>
<td>G319A</td>
<td>E107K</td>
<td>Propeptide</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>44T</td>
<td>5</td>
<td>G851A</td>
<td>R284K</td>
<td>None</td>
</tr>
<tr>
<td>Gene</td>
<td>Ref Seq accession</td>
<td>CCDS accession</td>
<td>No. of mutations (% tumors affected)</td>
<td>Tumor</td>
<td>Exon</td>
<td>Nucleotide</td>
<td>Amino Acid</td>
<td>Functional domain</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------</td>
<td>----------------</td>
<td>-------------------------------------</td>
<td>-------</td>
<td>------</td>
<td>------------</td>
<td>------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>ADAMTS19</td>
<td>NM_133638.3</td>
<td>CCDS4146.1</td>
<td>3 (3.8%)</td>
<td>63T</td>
<td>5</td>
<td>G860A</td>
<td>G287E</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>23T</td>
<td>5</td>
<td>G935A</td>
<td>G312E</td>
<td>Reprolysin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12T</td>
<td>9</td>
<td>C1354T</td>
<td>P452S</td>
<td>Reprolysin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17T</td>
<td>13</td>
<td>T1912A</td>
<td>C638S/LOH</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10T</td>
<td>13</td>
<td>G1969A</td>
<td>E657K</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>36T</td>
<td>14</td>
<td>G2061T</td>
<td>K687N</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>55T</td>
<td>14</td>
<td>T2081A</td>
<td>F694Y</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>98T</td>
<td>18</td>
<td>C2710T</td>
<td>Q904X</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>85T</td>
<td>19</td>
<td>C3004T</td>
<td>Q1002X</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>104T</td>
<td>20</td>
<td>C3103T</td>
<td>P1055S</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>71T</td>
<td>21</td>
<td>G3281A</td>
<td>R1094Q</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7T</td>
<td>23</td>
<td>C3556T</td>
<td>P1186S</td>
<td>None</td>
</tr>
<tr>
<td>ADAMTS20</td>
<td>NM_025003</td>
<td>CCDS31778.1</td>
<td>12 (11.4%)</td>
<td>48T</td>
<td>2</td>
<td>C203T</td>
<td>S68F</td>
<td>Propeptide</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>32T</td>
<td>4</td>
<td>G684A</td>
<td>M228I</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>39T</td>
<td>8</td>
<td>C1124T</td>
<td>S375L</td>
<td>Reprolysin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>83T</td>
<td>10</td>
<td>C1442T</td>
<td>S481L</td>
<td>ADAM cysteine-rich domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22T</td>
<td>11</td>
<td>G1610A</td>
<td>G537E</td>
<td>ADAM cysteine-rich domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>74T</td>
<td>13</td>
<td>G1771A</td>
<td>G591R</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17T</td>
<td>14</td>
<td>C1957T</td>
<td>R653C</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>106T</td>
<td>22</td>
<td>C3133T</td>
<td>R1044W</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>39T</td>
<td>30</td>
<td>G4489A</td>
<td>D1497N</td>
<td>Thrombospondin type 1 domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>55T</td>
<td>36</td>
<td>A5350G</td>
<td>R1784G</td>
<td>GON domain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>55T</td>
<td>38</td>
<td>G5608A</td>
<td>G1870R</td>
<td>GON domain</td>
</tr>
</tbody>
</table>

* Accession numbers for mutated ADAMTSs in Santa Cruz and GenBank.

† Number of non-synonymous mutations observed and percent of tumors affected for each of the 11 genes in the panel of 79 melanoma cancers.

‡ Nucleotide and amino acid change resulting from mutation.
"X" refers to stop codon. "LOH" refers to cases wherein the wild-type allele was lost and only the mutant allele remained. "None" refers to mutations outside any identifiable domain.